Anteris Technologies Global Corp.

Anteris Technologies Global Corp.

AVRNYSE / NASDAQHealthcareSmall cap

$4.99-$0.10 (-2.0%)

Last close · Data as of Nov 20, 2026

Market cap
$939.4M
Net margin
-1685.7%
ROCE
-240.8%

+47.6% over the last year

Anteris Technologies Global Corp. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-20.7%
3M
-46.1%
6M
-42.1%
1Y
+47.6%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.10 (-2.0%) from $5.09 to $4.99 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AVR, bought on each weekday since 2024.

News & filings

What Anteris Technologies Global filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernEV / Sales of 337.0 is more than ten times the peer median of 1.5.

Strengths (1)

  • Current assets are 2.56 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.

Read moreShow less

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Sector
Healthcare
Shares outstanding
35.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$939.4M
P/B
48.7x
EV / Sales
337.0x
P/S
344.1x
52-week high
$10.57
52-week low
$3.38

Profitability

Operating margin
-1709.2%
Net margin
-1685.7%
EBITDA margin
-1668.1%
ROE
-238.4%
ROCE
-240.8%
ROA
-150.7%
Asset turnover
0.09

Growth

Revenue growth, 1Y
0.0%
Net profit growth, 1Y
0.0%

Solvency

Current ratio
2.56
Debt / Equity
0.09
Debt / Assets
0.06
CFO / Net profit
0.75
Cash / Market cap
2.2%

Revenue and net profit

Revenue grew 0.0% in FY2025; net profit is the dashed line.

Anteris Technologies Global Corp. revenue and net profit by fiscal year
Anteris Technologies Global Corp. revenue and net profit by fiscal year
DateRevenueNet profit
FY2021$5.8M-$17.2M
FY2022$3.2M-$30.6M
FY2023$2.7M-$46.0M

Cash flows

Cash from operations, with free cash flow as the dashed line.

Anteris Technologies Global Corp. operating and free cash flow by fiscal year
Anteris Technologies Global Corp. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2021-$14.4M-$15.0M
FY2022-$29.4M-$31.1M
FY2023-$34.6M-$37.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025—————0.0%0.0%

Monthly returns

Month-by-month returns of AVR across the years, with the seasonal pattern.

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AVR highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Anteris Technologies Global Corp. (this company)337.0x

Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Annexon, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Anteris Technologies Global Corp.AVRthis company$939.4M—48.7x-238.4%—
Corvus Pharmaceuticals, Inc.CRVS$985.5M-64.5x16.1x-25.0%-22.9x
InnovAge Holding Corp.INNV$977.3M-32.2x4.2x-12.9%-102.4x
U.S. Physical Therapy, Inc.USPH$940.1M62.4x2.0x3.2%11.1x
Olema Pharmaceuticals, Inc.OLMA$932.9M-5.7x1.9x-33.9%-5.0x
Nutex Health Inc.NUTX$929.7M13.1x2.8x21.5%3.8x
ARS Pharmaceuticals, Inc.SPRY$900.7M-5.3x7.9x-149.9%-5.7x
Annexon, Inc.ANNX$892.9M-4.3x4.2x-97.7%-3.5x
Pacira BioSciences, Inc.PCRX$892.0M126.9x1.3x1.0%8.7x
Peer median—-4.8x3.5x-18.9%-4.3x

Year-to-date ROI

AVR since 1 January, against earlier years.

Historical volatility

AVR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Anteris Technologies Global Corp. operating margin by fiscal year
Anteris Technologies Global Corp. operating margin by fiscal year
DateOperating margin
FY2021-279.9%
FY2022-984.1%
FY2023-1709.2%
FY2024—
FY2025—
LineFY2025
Cost of revenueCost Of Revenue—
Gross profitGross Profit—
Operating expensesOperating Expense—
Research and developmentResearch And Development—
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement—
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement—
Insurance and claimsInsurance And Claims—
Total expensesTotal Expenses—
Pretax incomePretax Income—

Learn while you research

Academy chapters picked for Anteris Technologies Global Corp. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →